Heart failure in adult with congenital heart disease is an important cause of morbi-mortality. Sacubitril/Valsartan has been validated for the treatment of heart failure in adults with left ventricular dysfunction.
The aim of this study was to assess safety and efficacy of Sacubitril/Valsartan in symptomatic adults with systemic right ventricle dysfunction.
This is a retrospective and single center study (Quebec Heart and Lung Institute, Quebec City, Canada).
Eight patients (mean age 41±9.2 years, 5 males) with a significant systemic right ventricle dysfunction in New-York functional class II-III despite optimal heart failure medication were included. Sacubitril/Valsartan was up titrated at the maximal dosage tolerated. The mean dosage reached was 85±22mg/90±24mg. During a median follow-up of 248 (213 - 430) days, systolic (121±13 vs. 116±13mmHg, P=0.238) and diastolic (76±6mmHg vs. 72±5mmHg, P=0.105) blood pressure, potassium (4.1±0.4mmol/l vs. 3.9±0.2mmol/l, P=0.111) and creatinine (71.7±14.5μmol/l vs. 68.9±14.7μmol/l, P=0.516) levels remained stable. No discontinuation, reduction in dose or side effects were noted. A significant improvement in functional status was observed (P=0.03): 6 patients had a New-York Heart Association class improvement and 2 remained in the same class (Fig. 1). Maximal oxygen uptake, NTproBNP levels and echocardiographic data did not reach significant improvement.
Sacubitril/Valsartantitration in a population of patients with congenital heart disease and significant right ventricle dysfunction was well tolerated and associated with significant improvement in functional status class. Whether Sacubitril/Valsartan improved right ventricle remodeling or decrease heart failure hospitalization or mortality in that population remained to determined.
Le texte complet de cet article est disponible en PDF.
Publié par Elsevier Masson SAS.